Business Description
Xenon Pharmaceuticals is a Canadian drug development company focused on treating brain and mental health conditions, founded in 1996 and based in Burnaby, Canada. Its most advanced drug candidate, Azetukalner, is currently in late-stage clinical trials for epilepsy and conditions such as major depressive disorder and bipolar depression. The company also has earlier-stage programs targeting pain relief, alongside a partnership with Neurocrine Biosciences to develop a treatment for certain forms of epilepsy.
